<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01203644</url>
  </required_header>
  <id_info>
    <org_study_id>SKY0402-C-201</org_study_id>
    <nct_id>NCT01203644</nct_id>
  </id_info>
  <brief_title>Evaluation of the Safety, Efficacy, and Pharmacokinetics of SKY0402 in Subjects Undergoing Inguinal Hernia Repair</brief_title>
  <official_title>A Phase 2, Multicenter, Randomized, Double Blind, Dose Escalating/ De Escalating Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of a Single Dose of Sustained Release Encapsulated Bupivacaine (SKY0402) in the Management of Postoperative Pain in Subjects Undergoing Inguinal Hernia Repair</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pacira Pharmaceuticals, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pacira Pharmaceuticals, Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study was to determine the appropriate dose of SKY0402 for the
      management of postoperative pain following inguinal hernia repair. This study evaluated the
      safety, efficacy, and pharmacokinetics of SKY0402 compared with a 100 mg dose of bupivacaine
      HCl for the treatment of postoperative pain in subjects undergoing inguinal hernia repair.
      Study drug was administered by surgical wound infiltration at the end of the hernia repair
      procedure.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      SKY0402 was administered in a dose escalating/de-escalating fashion, with a low starting dose
      in Cohort 1 that was to be increased or decreased in subsequent cohorts based on safety and
      analgesic effects. The decision to proceed to the next cohort (i.e., increase or decrease the
      dose) was made by a Cohort Data Review Committee following a review of the data from the
      previous cohort. Subjects were randomized to receive either SKY0402 or bupivacaine HCl at a
      ratio of 1:1 in Cohort 1 and at a ratio of 3:1 in subsequent cohorts. The dose of bupivacaine
      HCl (100 mg) remained constant for all cohorts.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2004</start_date>
  <completion_date type="Actual">December 2006</completion_date>
  <primary_completion_date type="Actual">January 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to First Use of Supplemental Pain Medication</measure>
    <time_frame>Through 96 hours postdose</time_frame>
    <description>The primary efficacy endpoint was the time to first use of supplemental pain medication (opioid or non-opioid) postoperatively for surgical wound pain</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>Through 30 days postdose</time_frame>
    <description>Safety assessments included monitoring of treatment-emergent adverse events</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">76</enrollment>
  <condition>Inguinal Hernia</condition>
  <arm_group>
    <arm_group_label>Bupivacaine HCl</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>(e.g., Marcaine with epinephrine 1:200,000) is the reference-listed drug for bupivacaine and contains the same active, local anesthetic as SKY0402</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SKY0402</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Low dose, low-mid dose, mid-dose, and high dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SKY0402</intervention_name>
    <description>Single dose of SKY0402 administered locally into the surgical wound.</description>
    <arm_group_label>Bupivacaine HCl</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupivacaine HCl</intervention_name>
    <description>Single dose of bupivacaine HCl (100 mg) administered locally into the surgical wound.</description>
    <arm_group_label>SKY0402</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Males â‰¥18 years of age at the Screening visit.

          2. Scheduled to undergo unilateral inguinal hernia repair under general anesthesia, using
             an open, tension free procedure (e.g., Lichtenstein technique with or without mesh).

          3. American Society of Anesthesiology (ASA) Physical Class 1 or 2.

          4. Able and willing to comply with all study visits and procedures.

          5. Capable of speaking and understanding the local language sufficiently to provide
             responses to pain assessment scales.

          6. Willing and capable of providing written informed consent.

        Exclusion Criteria:

          1. Clinically significant electrocardiogram abnormalities at Screening or on Day 1 (pre
             administration).

          2. Albumin and/or alpha 1 acid glycoprotein (AAG) below normal levels.

          3. Current or historical evidence of any clinically significant disease or condition
             that, in the opinion of the Investigator, might have increased the risk of surgery or
             complicated the subject's postoperative course.

          4. Opioid medication usage during the 7 day period preceding the administration of study
             drug.

          5. Current medical conditions that could have required treatment with analgesic
             medications in the postoperative period for pain that was not surgically related
             (e.g., rheumatoid arthritis).

          6. Body mass index &gt;30 mg/kg2.

          7. Body weight &lt;60 kg.

          8. History of hypersensitivity or idiosyncratic reaction to amide type local anesthetic
             agents.

          9. History of hypersensitivity, idiosyncratic reactions, and other contraindications to
             the pain control agents (opioid or non-opioid) anticipated to be used postoperatively.
             These contraindications may have included: angioedema and bronchospastic reactivity to
             non steroidal anti inflammatory drug, peptic ulcer (active within the last three
             months), hepatic or renal insufficiency.

         10. Coagulation disorders or ongoing anticoagulation treatment.

         11. Administration of an investigational drug within 30 days or five half lives (of
             elimination), whichever was longer, prior to study drug administration.

         12. Suspected or known history of substance abuse and/or alcoholism.

         13. Clinically significant complications during the hernia repair surgery (e.g., excessive
             bleeding), which might have rendered the subject medically unstable or might have
             complicated the subject's postoperative course.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kay Warnott, RN, ACNP</last_name>
    <role>Study Director</role>
    <affiliation>Pacira Pharmaceuticals, Inc</affiliation>
  </overall_official>
  <verification_date>November 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 15, 2010</study_first_submitted>
  <study_first_submitted_qc>September 15, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2010</study_first_posted>
  <results_first_submitted>November 23, 2011</results_first_submitted>
  <results_first_submitted_qc>April 15, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 14, 2012</results_first_posted>
  <disposition_first_submitted>September 22, 2010</disposition_first_submitted>
  <disposition_first_submitted_qc>September 22, 2010</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">September 27, 2010</disposition_first_posted>
  <last_update_submitted>April 15, 2012</last_update_submitted>
  <last_update_submitted_qc>April 15, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 14, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Postoperative pain</keyword>
  <keyword>Analgesia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hernia</mesh_term>
    <mesh_term>Hernia, Inguinal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupivacaine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Bupivacaine HCl</title>
          <description>(e.g., Marcaine with epinephrine 1:200,000) is the reference-listed drug for bupivacaine and contains the same active, local anesthetic as SKY0402</description>
        </group>
        <group group_id="P2">
          <title>SKY0402</title>
          <description>Low dose, low-mid dose, mid-dose, and high dose</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Bupivacaine HCl</title>
          <description>(e.g., Marcaine with epinephrine 1:200,000) is the reference-listed drug for bupivacaine and contains the same active, local anesthetic as SKY0402</description>
        </group>
        <group group_id="B2">
          <title>SKY0402</title>
          <description>Low dose, low-mid dose, mid-dose, and high dose</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="26"/>
            <count group_id="B2" value="50"/>
            <count group_id="B3" value="76"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51.3" spread="12.6"/>
                    <measurement group_id="B2" value="55.1" spread="16"/>
                    <measurement group_id="B3" value="53.8" spread="14.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="50"/>
                    <measurement group_id="B3" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Belgium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Australia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Netherlands</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Time to First Use of Supplemental Pain Medication</title>
        <description>The primary efficacy endpoint was the time to first use of supplemental pain medication (opioid or non-opioid) postoperatively for surgical wound pain</description>
        <time_frame>Through 96 hours postdose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bupivacaine HCl</title>
            <description>(e.g., Marcaine with epinephrine 1:200,000) is the reference-listed drug for bupivacaine and contains the same active, local anesthetic as SKY0402. Single 100 mg administration of 0.25% solution (i.e., 0.5% diluted 1:1) in a 40-mL volume via local infiltration</description>
          </group>
          <group group_id="O2">
            <title>SKY0402 Low Dose</title>
            <description>Single administration of SKY0402 (low dose) in a 40-mL volume via local infiltration</description>
          </group>
          <group group_id="O3">
            <title>SKY0402 Low-mid Dose</title>
            <description>Single administration of SKY0402 (low-mid dose) in a 40-mL volume via local infiltration</description>
          </group>
          <group group_id="O4">
            <title>SKY0402 High-mid Dose</title>
            <description>Single administration of SKY0402 (high-mid dose) in a 40-mL volume via local infiltration</description>
          </group>
          <group group_id="O5">
            <title>SKY0402 High Dose</title>
            <description>Single administration of SKY0402 (high dose) in a 40-mL volume via local infiltration</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First Use of Supplemental Pain Medication</title>
          <description>The primary efficacy endpoint was the time to first use of supplemental pain medication (opioid or non-opioid) postoperatively for surgical wound pain</description>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.2" lower_limit="1.3" upper_limit="13.7"/>
                    <measurement group_id="O2" value="13.75" lower_limit="2.1" upper_limit="62.7"/>
                    <measurement group_id="O3" value="3.9" lower_limit="0.8" upper_limit="7.4"/>
                    <measurement group_id="O4" value="5.2" lower_limit="1.9" upper_limit="18.8"/>
                    <measurement group_id="O5" value="5.5" lower_limit="1.4" upper_limit="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adverse Events</title>
        <description>Safety assessments included monitoring of treatment-emergent adverse events</description>
        <time_frame>Through 30 days postdose</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Bupivacaine HCl</title>
          <description>(e.g., Marcaine with epinephrine 1:200,000) is the reference-listed drug for bupivacaine and contains the same active, local anesthetic as SKY0402</description>
        </group>
        <group group_id="E2">
          <title>SKY0402</title>
          <description>Low dose, low-mid dose, mid-dose, and high dose</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Postoperative hematoma</sub_title>
                <description>Occurred in the low-mid dose group</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary Retention/BPH</sub_title>
                <description>Occurred in the high-mid dose group</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Localized oedema</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Executive Medical Director</name_or_title>
      <organization>Pacira Pharmaceuticals, Inc.</organization>
      <phone>203-837-6500</phone>
      <email>ErolOnel@pacira.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

